Patrick Wood
Stock Analyst at Morgan Stanley
(3.02)
# 1,330
Out of 5,115 analysts
119
Total ratings
50%
Success rate
0.48%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Overweight | $48 | $44.20 | +8.60% | 1 | Jan 12, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $81.38 | +1.99% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $133.98 | +0.77% | 3 | Dec 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $17 → $23 | $19.89 | +15.64% | 6 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $8.69 | +15.07% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $28.96 | +76.10% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $73.04 | +2.68% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $203.48 | +3.20% | 6 | Dec 2, 2025 | |
| BAX Baxter International | Maintains: Underweight | $19 → $15 | $20.07 | -25.26% | 6 | Dec 2, 2025 | |
| BLCO Bausch + Lomb | Upgrades: Overweight | $14 → $21 | $16.70 | +25.75% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $80 | $78.97 | +1.30% | 8 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $130 | $93.53 | +38.99% | 7 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $80.98 | -1.21% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $262.60 | +12.34% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $81.36 | -0.44% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $76.97 | +33.82% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $119.38 | -39.69% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $104.37 | +65.76% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $255.81 | +23.92% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $2.20 | +354.55% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $18.95 | +95.25% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $109.34 | - | 5 | Dec 11, 2017 |
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $48
Current: $44.20
Upside: +8.60%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $81.38
Upside: +1.99%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $133.98
Upside: +0.77%
Tandem Diabetes Care
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $17 → $23
Current: $19.89
Upside: +15.64%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $8.69
Upside: +15.07%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $28.96
Upside: +76.10%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $73.04
Upside: +2.68%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $203.48
Upside: +3.20%
Baxter International
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $20.07
Upside: -25.26%
Bausch + Lomb
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.70
Upside: +25.75%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $74 → $80
Current: $78.97
Upside: +1.30%
Oct 23, 2025
Maintains: Overweight
Price Target: $125 → $130
Current: $93.53
Upside: +38.99%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $80.98
Upside: -1.21%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $262.60
Upside: +12.34%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $81.36
Upside: -0.44%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $76.97
Upside: +33.82%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $119.38
Upside: -39.69%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $104.37
Upside: +65.76%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $255.81
Upside: +23.92%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $2.20
Upside: +354.55%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $18.95
Upside: +95.25%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $109.34
Upside: -